Form 4: OnKure Director Boosts Stake with RSU Conversion

OnKure Therapeutics Director Edward T Mathers acquired 3,911 shares of Class A Common Stock through vested restricted stock units as part of his compensation.

Summary

• Edward T Mathers, a Director at OnKure Therapeutics, Inc. (OKUR), acquired 3,911 shares of Class A Common Stock.
• The acquisition occurred on December 31, 2025, and was made pursuant to a Rule 10b5-1 plan.
• These shares were received as fully vested restricted stock units (RSUs) in lieu of a quarterly cash retainer.
• The RSUs were granted at the Reporting Person's election under the Issuer's Outside Director Compensation Policy.
• Following this transaction, Edward T Mathers beneficially owns a total of 15,310 shares of Class A Common Stock.

Sentiment

Score: 6

Explanation: Slightly positive, as a director is increasing their stake in the company, aligning their interests with shareholders, which is generally viewed favorably.

Positives

• The Director's decision to receive compensation in stock rather than cash demonstrates an increased alignment of his interests with those of the company's shareholders.
• The acquisition of additional shares by a director can signal confidence in the company's future prospects.

Negatives

• No specific negative aspects are directly indicated by this routine insider transaction filing.

Industry Context

This transaction reflects a common practice in corporate governance where non-employee directors receive equity-based compensation, such as restricted stock units, to align their financial interests with the long-term performance of the company and its shareholders. This is a standard component of director compensation policies across various industries.

Comparison to Industry Standards

• Granting restricted stock units (RSUs) to directors as part of their compensation, often in lieu of cash retainers, is a common and widely accepted practice across various industries, particularly in growth-oriented companies like those in the biotechnology and pharmaceutical sectors.
• This method is favored for aligning the interests of directors with those of shareholders by tying a portion of their compensation directly to the company's stock performance, a strategy employed by many public companies.

Stakeholder Impact

• Shareholders: The increased ownership by a director may be viewed positively as it aligns management's interests with shareholder value.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Keywords

OnKure Therapeutics, OKUR, Edward T Mathers, Director, Insider Transaction, Form 4, Restricted Stock Units, RSU, Equity Compensation, Stock Acquisition